Stockscreener 앱 받기
50.67
2.76%
1.36
시간 외 거래:
50.67
Vaxcyte Inc 주식(PCVX)의 최신 뉴스
Vaxcyte (PCVX) AGM 2026 Summary - Quartr
PCVX: All proposals passed with strong support and no shareholder questions were raised - TradingView
PCVX: All board proposals passed with a strong quorum and no shareholder questions raised - TradingView
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
TD Asset Management Inc Cuts Stock Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc. (PCVX) Stock Analysis: A Biotech With A Promising 130% Upside Potential - DirectorsTalk Interviews
Norges Bank Invests $56.70 Million in Vaxcyte, Inc. $PCVX - MarketBeat
Average basic shares outstanding of Vaxcyte, Inc. – XETR:5VA - TradingView
Net current asset value per share of Vaxcyte, Inc. – XETR:5VA - TradingView
Total assets of Vaxcyte, Inc. – XETR:5VA - TradingView
EBIT per share of Vaxcyte, Inc. – XETR:5VA - TradingView
Vaxcyte, Inc. Balance Sheet – XETR:5VA - TradingView
Vaxcyte, Inc. Statistics – XETR:5VA - TradingView
Vaxcyte, Inc. Dividends – XETR:5VA - TradingView
Discipline and Rules-Based Execution in PCVX Response - Stock Traders Daily
Westfield Capital Management Co. LP Lowers Position in Vaxcyte, Inc. $PCVX - MarketBeat
PCVX News | VAXCYTE INC (NASDAQ:PCVX) - ChartMill
Does Vaxcyte’s First-in-Human Group A Strep Trial Reshape The Bull Case For Vaxcyte (PCVX)? - simplywall.st
Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Vaxcyte (PCVX) and BeOne Medicines (ONC) - The Globe and Mail
Insider Sell Alert: Jim Wassil Sells Shares of Vaxcyte Inc (PCVX) - GuruFocus
Vaxcyte COO Jim Wassil sells $111k in PCVX stock - Investing.com UK
Vaxcyte COO Jim Wassil sells $111k in PCVX stock By Investing.com - Investing.com India
COO of Vaxcyte (NASDAQ: PCVX) sells 2,250 shares in pre-set plan - Stock Titan
Mizuho Securities Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $163 - Moomoo
Vaxcyte (PCVX) Takes First Steps in Human Vaccine Trials - GuruFocus
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults - Investing News Network
Vaxcyte Doses First Participant In Phase 1 Study Evaluating Vax-A1 For The Prevention Of Disease Caused By Group A Streptococcus In Healthy Adults - TradingView
Vaxcyte Begins Phase 1 Clinical Trial for Group A Streptococcus Vaccine Candidate VAX-A1 - geneonline.com
Vaxcyte doses first participant in group A strep vaccine trial - Investing.com
Vaxcyte doses first participant in group A strep vaccine trial By Investing.com - Investing.com Australia
Vaxcyte Doses First Participant in Phase 1 Study Evaluating - GlobeNewswire
Vaxcyte Inc stock (US92242T1016): Q1 2026 results and outlook ahead of next earnings date - AD HOC NEWS
PCVX insider sales disclosed: James Wassil sold 11,895 shares (PCVX) - Stock Titan
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring a Promising 112% Upside in the Biotech Sector - DirectorsTalk Interviews
Why Vaxcyte (PCVX) Is Up 8.7% After Completing Key VAX-31 Phase 3 Trial Enrollments - Yahoo Finance
Vaxcyte Inc stock (US92242T1016): shares steady as Phase 3 pneumonia vaccine program advances - AD HOC NEWS
Assessing Vaxcyte (PCVX) Valuation After Mixed Short And Long Term Share Price Moves - simplywall.st
Vaxcyte (PCVX) Completes Enrollment for Phase 3 VAX-31 Clinical Trials - Yahoo Finance
Vaxcyte Inc. (PCVX) Slips 1.4% as Shares Test Key Support ZoneMA Cross Alert - The Legal Advocate
Top 3 Health Care Stocks You'll Regret Missing In MayVaxcyte (NASDAQ:PCVX), Universal Health Services - Benzinga
Behavioral Patterns of PCVX and Institutional Flows - Stock Traders Daily
Vaxcyte, Inc. (PCVX) Stock Analysis: Unpacking a 130% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Vaxcyte stock (US92242T1016): clinical-stage vaccine developer draws attention after recent capital - AD HOC NEWS
Vaxcyte (PCVX) slips 3.8% as investors digest recent ownership filings and cash-burn outlook - Quiver Quantitative
Why Vaxcyte (PCVX) Is Down 9.7% After Steeper Q1 Losses And Accelerated R&D Spending - simplywall.st
Pfizer Expands Pneumococcal Vaccine Push With New Programs - Benzinga
Vaxcyte, Inc. (PCVX) Stock Analysis: Biotech Innovator With Over 100% Upside Potential - DirectorsTalk Interviews
Vaxcyte Inc stock (US92242T1016): fresh data from pneumococcal vaccine program keeps biotech in focu - AD HOC NEWS
Vaxcyte stock (US92242T1016): Pneumococcal vaccine data keeps investors focused - AD HOC NEWS
RA Capital reports 12.97M shares in Vaxcyte (NASDAQ: PCVX) - Stock Titan
Janus Henderson (PCVX) discloses 16.6M shares, 11.5% ownership - Stock Titan
Jones Hill Capital LP's Vaxcyte Inc(PCVX) Holding History - GuruFocus
2.60%
0.94%
자본화:
|
볼륨(24시간):